Ovation’s ovarian cancer diagnostic technology is supported by a robust portfolio of patents. It is the only patented technology for measuring Bcl-2 levels in urine for the purpose of detecting ovarian cancer.

The US patent was granted in 2011 and it is supported by international patents in the following countries:

    • Brazil
    • China
    • Germany
    • India
    • Canada
    • France
    • Great Britain
    • Mexico